New hope for elderly lymphoma patients: drug cocktail targets aggressive cancer
NCT ID NCT07415980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—polatuzumab vedotin, rituximab, and chidamide—in elderly patients (70+ or frail 60-69) with untreated diffuse large B-cell lymphoma that has two specific markers (MYC and BCL2). The goal is to see if this mix is safe and effective, aiming for complete remission. It is an early-phase trial with 68 participants, so results will guide future research rather than provide immediate new treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- polatuzumab vedotin, rituximab, and chidamide
- What this could lead to
- If successful, this could offer a new, less toxic treatment option for elderly patients with a hard-to-treat lymphoma type.
- What could go wrong
- This is an early-phase trial (phase 1b/2) with only 68 participants, so results may not confirm safety or effectiveness. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE EXPRESSOR DLBCL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.